{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:34:51Z","timestamp":1778704491066,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-025-03616-3","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:07:42Z","timestamp":1740035262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of vaginal suppositories containing combination of Natamycin and Lactulose in treatment of vulvovaginal candidiasis: international, randomized, controlled, superiority clinical trial (combination of Natamycin and Lactulose for treatment of vulvovaginal candidiasis)"],"prefix":"10.1186","volume":"25","author":[{"given":"Oksana N.","family":"Volkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena V.","family":"Amel\u2019chenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oksana V.","family":"Makeeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey A.","family":"Tolmachev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina A.","family":"Lesovaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lefteris C.","family":"Zacharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Dikovskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"3616_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12905-019-0748-8","volume":"19","author":"J Yano","year":"2019","unstructured":"Yano J, Sobel JB, Nyirjesy P, Sobel R, Williams VL, Yu Q, Noverr MC, et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and posttreatment outcomes. BMC Womens Health. 2019;19:48. https:\/\/doi.org\/10.1186\/s12905-019-0748-8.","journal-title":"BMC Womens Health"},{"key":"3616_CR2","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","volume":"18","author":"DW Denning","year":"2018","unstructured":"Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18:e339\u201347. https:\/\/doi.org\/10.1016\/S1473-3099(18)30103-8.","journal-title":"Lancet Infect Dis"},{"key":"3616_CR3","doi-asserted-by":"publisher","first-page":"575e","DOI":"10.1016\/j.annepidem.2017.08.010","volume":"27","author":"F Blostein","year":"2017","unstructured":"Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27:575e\u2013582. https:\/\/doi.org\/10.1016\/j.annepidem.2017.08.010.","journal-title":"Ann Epidemiol"},{"issue":"9","key":"3616_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/14656566.2018.1476490","volume":"19","author":"JD Sobel","year":"2018","unstructured":"Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother. 2018;19(9):971\u20137. https:\/\/doi.org\/10.1080\/14656566.2018.1476490.","journal-title":"Expert Opin Pharmacother"},{"key":"3616_CR5","doi-asserted-by":"publisher","unstructured":"Sun Z, Ge X, Qiu B, Xiang Z, Jiang C, Wu J, Li Y. Vulvovaginal candidiasis and vaginal microflora interaction. Microflora changes and probiotic therapy. Front Cell Infect Microbiol. 2023; 13:1123026. https:\/\/doi.org\/10.3389\/fcimb.2023.1123026.","DOI":"10.3389\/fcimb.2023.1123026"},{"key":"3616_CR6","doi-asserted-by":"publisher","unstructured":"Kalia1 N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020; 19:5. https:\/\/doi.org\/10.1186\/s12941-020-0347-4.","DOI":"10.1186\/s12941-020-0347-4"},{"key":"3616_CR7","doi-asserted-by":"publisher","unstructured":"Borisa S, Barb\u00e9sb C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes and Infection. 2000; 543\u2212546. https:\/\/doi.org\/10.1016\/S1286-4579(00)00313-0.","DOI":"10.1016\/S1286-4579(00)00313-0"},{"issue":"2","key":"3616_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4161\/viru.22913","volume":"4","author":"FL Mayer","year":"2013","unstructured":"Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119\u201328. https:\/\/doi.org\/10.4161\/viru.22913.","journal-title":"Virulence"},{"key":"3616_CR9","doi-asserted-by":"publisher","unstructured":"Felix TC, R\u00f6der DVDDB, Pedroso RDS. Alternative and complementary therapies for vulvovaginal candidiasis. Folia Microbiol. 2019. https:\/\/doi.org\/10.1007\/s12223-018-0652-x.","DOI":"10.1007\/s12223-018-0652-x"},{"key":"3616_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/myc.12883","volume":"62","author":"R Russo","year":"2019","unstructured":"Russo R, Superti F, Karadja E, Seta FD. Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019;62:328\u201335. https:\/\/doi.org\/10.1111\/myc.12883.","journal-title":"Mycoses"},{"key":"3616_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0884217503253439","volume":"32","author":"HS Jeavons","year":"2003","unstructured":"Jeavons HS. Prevention and Treatment of Vulvovaginal Candidiasis Using Exogenous Lactobacillus. JOGNN. 2003;32:287\u201396. https:\/\/doi.org\/10.1177\/0884217503253439.","journal-title":"JOGNN"},{"key":"3616_CR12","doi-asserted-by":"publisher","unstructured":"Jeng H-S, Yan T-R, Chen J-Y. Treating vaginitis with probiotics in non\u2011pregnant females: A systematic review and meta\u2011analysis. Experimental and Therapeutic Medicine. 2020; 3749\u22123765. https:\/\/doi.org\/10.3892\/etm.2020.9090.","DOI":"10.3892\/etm.2020.9090"},{"key":"3616_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-014-9749-1","author":"N Martins","year":"2014","unstructured":"Martins N, Ferreira ICFR, Barros L, Silva S, Henriques M. Candidiasis: Predisposing Factors, Prevention, Diagnosis and Alternative Treatment. Mycopathologia. 2014. https:\/\/doi.org\/10.1007\/s11046-014-9749-1.","journal-title":"Mycopathologia"},{"key":"3616_CR14","unstructured":"SPC Pimafucin 100 mg vaginal suppositories. 2018. https:\/\/myhealthbox.eu\/en\/pimafucin-suppositories-vaginal\/459282. Accessed 15 Dec 2023."},{"key":"3616_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-013-4998-3","author":"H Wang","year":"2013","unstructured":"Wang H, Yang R, Hua X, Zhao W, Zhang W. Enzymatic production of lactulose and 1-lactulose: currentstate and perspectives. Appl Microbiol Biotechnol. 2013. https:\/\/doi.org\/10.1007\/s00253-013-4998-3.","journal-title":"Appl Microbiol Biotechnol"},{"key":"3616_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijfoodmicro.2010.11.011","volume":"145","author":"RPDS Oliveira","year":"2011","unstructured":"Oliveira RPDS, Florence ACR, Perego P, Oliveira MND, Converti A. Use of lactulose as prebiotic and its influence on the growth, acidification profile and viable counts of different probiotics in fermented skim milk. Int J Food Microbiol. 2011;145:22\u20137. https:\/\/doi.org\/10.1016\/j.ijfoodmicro.2010.11.011.","journal-title":"Int J Food Microbiol"},{"key":"3616_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/nu12041037","volume":"12","author":"MPL Guarino","year":"2020","unstructured":"Guarino MPL, Altomare A, Emerenziani S, Rosa CD, Ribolsi M, Balestrieri P, Iovino P, et al. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients. 2020;12:1037. https:\/\/doi.org\/10.3390\/nu12041037.","journal-title":"Nutrients"},{"issue":"1","key":"3616_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1079\/bjn19790010","volume":"41","author":"DF Evered","year":"1979","unstructured":"Evered DF, Sadoogh-Abasian F. Absorption of lactulose from mammalian gastrointestinal tract. Br J Nutr. 1979;41(1):47\u201351. https:\/\/doi.org\/10.1079\/bjn19790010.","journal-title":"Br J Nutr"},{"key":"3616_CR19","unstructured":"FDA. Vulvovaginal Candidiasis: Developing Drugs for Treatment Guidance for Industry. 2019. https:\/\/www.fda.gov\/media\/129537\/download. Accessed 03 Jun 2022."},{"key":"3616_CR20","doi-asserted-by":"publisher","unstructured":"Vylkova S, Carman AJ, Danhof HA, Collette JR, Zhou H, Lorenz MC. The fungal pathogen Candida albicans autoinduces hyphal morphogenesis by raising extracellular pH. mBio. 2011; 17:2(3): e00055\u221211. https:\/\/doi.org\/10.1128\/mBio.00055-11.","DOI":"10.1128\/mBio.00055-11"},{"key":"3616_CR21","doi-asserted-by":"publisher","unstructured":"Zhou X, Westman R, Hickey R, Hansmann MA. Kennedy C, Osborn TW, Forney LJ. Vaginal Microbiota of Women with Frequent Vulvovaginal Candidiasis. Infection and immunity. 2009; 4130\u20134135. https:\/\/doi.org\/10.1128\/IAI.00436-09.","DOI":"10.1128\/IAI.00436-09"},{"issue":"11","key":"3616_CR22","doi-asserted-by":"publisher","first-page":"e79812","DOI":"10.1371\/journal.pone.0079812","volume":"8","author":"M-B Liu","year":"2013","unstructured":"Liu M-B, Xu S-R, He Y, Deng G-H, Sheng H-F, Huang X-M, Ouyang C-Y, et al. Diverse Vaginal Microbiomes in Reproductive-Age Women with Vulvovaginal Candidiasis. PLoS ONE. 2013;8(11):e79812. https:\/\/doi.org\/10.1371\/journal.pone.0079812.","journal-title":"PLoS ONE"},{"issue":"5","key":"3616_CR23","doi-asserted-by":"publisher","first-page":"e02200","DOI":"10.1128\/AEM.02200-17","volume":"84","author":"SL Collins","year":"2018","unstructured":"Collins SL, McMillan A, Seney S, van der Veer C, Kort R, Sumarah MW, Reid G. Promising Prebiotic Candidate Established by Evaluation of Lactitol. Lactulose, Raffinose, and Oligofructose for Maintenance of a Lactobacillus-Dominated Vaginal Microbiota. 2018;84(5):e02200-e2217. https:\/\/doi.org\/10.1128\/AEM.02200-17.","journal-title":"Lactulose, Raffinose, and Oligofructose for Maintenance of a Lactobacillus-Dominated Vaginal Microbiota"},{"key":"3616_CR24","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1007\/s00203-021-02414-3","volume":"203","author":"VS Saraf","year":"2021","unstructured":"Saraf VS, Sheikh SA, Ahmad A, et al. Vaginal microbiome: normalcy vs dysbiosis. Arch Microbiol. 2021;203:3793\u2013802. https:\/\/doi.org\/10.1007\/s00203-021-02414-3.","journal-title":"Arch Microbiol"},{"key":"3616_CR25","doi-asserted-by":"publisher","first-page":"643422","DOI":"10.3389\/fmicb.2021.643422","volume":"12","author":"Y Han","year":"2021","unstructured":"Han Y, Liu Z, Chen T. Role of Vaginal Microbiota Dysbiosis in Gynecological Diseases and the Potential Interventions. Front Microbiol. 2021;12:643422. https:\/\/doi.org\/10.3389\/fmicb.2021.643422.","journal-title":"Front Microbiol"},{"issue":"12","key":"3616_CR26","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/jobm.202100421","volume":"61","author":"N Deka","year":"2021","unstructured":"Deka N, Hassan S, Seghal Kiran G, Selvin J. Insights into the role of vaginal microbiome in women\u2019s health. J Basic Microbiol. 2021;61(12):1071\u201384. https:\/\/doi.org\/10.1002\/jobm.202100421.","journal-title":"J Basic Microbiol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-03616-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-03616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:07:44Z","timestamp":1740035264000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-025-03616-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3616"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-03616-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4963521\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Natamycine\u2009+\u2009Lactulose-supp-12\/21 study (Permission # #482 from 11.08.2022) was conducted from December 2022 to July 2023 in two countries: the Russian Federation (one study site) and the Republic of Belarus (five study sites). Prior to subjects` enrollment, the ethical approval was obtained from the Ethics Review Board of the Russian Ministry of Health (Abstract of Record No. 305 of March 22, 2022) and local ethics committees (Statement w\/n of December 05, 2022 issued by the Institutional Review Board of Minsk Municipal Polyclinic No.4; Statement w\/n of November 28, 2022 issued by the Institutional Review Board of Minsk Municipal Outpatients Clinic No.5; Statement w\/n of December 05, 2022 issued by the Ethics Committee of Minsk Municipal Emergency Care Hospital; Statement w\/n of December 02, 2022 issued by the Institutional Review Board of Minsk Frunzenskiy District Central Polyclinic No.2; Statement w\/n of November 29, 2022 issued by the Institutional Review Board of Minsk Municipal Hospital No.1). The study was coordinated by the Department of Reproductive Medicine and Surgery at the A.I. Evdokimov Moscow State Medical and Dental University and performed in compliance with the World Medical Association Declaration of Helsinki and the International Conference on Harmonization guidelines (Good Clinical Practice).Prior to enrollment, all participants received written and verbal explanations of the study's aims, objectives, and methods, as well as the potential benefits and risks associated with participation. The subject and investigator completed the informed consent form in duplicate, with dated handwritten signatures. The investigator kept the first copy of the signed informed consent forms in the Investigator File, while the second copy was given to the subject. The study was reported in accordance with the Consolidated Standards for Reporting Trials (CONSORT) guidelines (Additional file 1). The study reached a pre-specified level of significance for the primary efficacy endpoint (\n                      P\n                      \u2009<\u20090.01556) and was terminated at the interim analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OVM, SAT and EAL are employees of AVVA RUS JSC that produce the combination suppositories.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}